ACRS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 Jul 2024 @ 16:00):
Our systems believe the stock currently is undervalued by 0.11% compare to its pairs and should correct upwards.

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States...

Stats
Today's Volume	1.65M
Average Volume	822 153
Market Cap	81.95M
EPS	$-0.240 ( Q1 \| 2024-05-07 )
Next earnings date	( $-0.190 ) 2024-08-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.060 (Sector) 42.63 (Industry) 0
ATR14	$0.00600 (0.52%)

ACRS 4.55%

AKU -17.87%

APDN 33.45%

BDSX 0.00%

BIOC 0.00%

BNGO -2.32%

BNR -0.16%

CDNA -0.97%

CEMI 0.22%

CHEK 3.03%

CNTG 2.73%

CSTL -2.66%

DMTK -11.32%

DRIO -1.68%

EXAS 0.43%

FLDM -7.02%

FLGT 2.14%

GENE -5.37%

GH -2.15%

GTH 0.12%

HTGM 0.00%

ICLR 0.97%

IDXX -2.22%

ILMN 1.07%

ISPC -1.91%

LAB -2.26%

LMDX 0.00%

MDXH -1.26%

ME -3.83%

MEDP -1.12%

MYGN -2.00%

MYNZ -13.92%

NDRA -4.43%

NEO 0.43%

NEOG -3.77%

NOTV -4.22%

NTRA -0.44%

OCDX 0.92%

OLK 0.27%

OPGN -2.98%

OPK -1.60%

PMD -2.89%

PRPO 6.01%

PSNL 2.14%

RDNT -0.63%

SERA 2.03%

SHC -2.44%

SQL 0.00%

STIM -2.78%

STRR -3.52%

STRRP -6.57%

SYNH 0.02%

TRIB 6.28%

TTOO 0.75%

TWST -0.71%

VIVO 0.00%

XGN -0.55%

Insider Trading

Date	Person	Action	Amount	type
2024-07-01	Leonard Braden Michael	Buy	107 434	Common Stock
2024-06-28	Leonard Braden Michael	Buy	400 000	Common Stock
2024-06-28	Leonard Braden Michael	Buy	801 000	Common Stock
2024-06-27	Leonard Braden Michael	Buy	235 000	Common Stock
2024-06-18	Leonard Braden Michael	Buy	50 000	Common Stock

INSIDER POWER
91.68
Last 98 transactions
Buy: 5 831 744 \| Sell: 275 614

Correlation (AI algo v.1.1b): Undervalued: 0.11% $1.151 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: 0.00 (neutral)

Short: 0.01 (neutral)

Signal:(10.277) Neutral

Aclaris Therapeutics Inc Correlation

10 Most Positive Correlations
OZEM	1

10 Most Negative Correlations
RFAIU	-0.839

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aclaris Therapeutics Inc Correlation - Currency/Commodity

-0.17
( neutral )

-0.15
( neutral )

0.00
( neutral )

-0.47
( neutral )

Aclaris Therapeutics Inc Financials

Annual	2023
Revenue:	$31.25M
Gross Profit:	$13.17M (42.14 %)
EPS:	$-1.270

FY	2023
Revenue:	$31.25M
Gross Profit:	$13.17M (42.14 %)
EPS:	$-1.270

FY	2022
Revenue:	$29.75M
Gross Profit:	$17.79M (59.80 %)
EPS:	$-1.360

FY	2021
Revenue:	$6.76M
Gross Profit:	$2.05M (30.29 %)
EPS:	$-2.14

Financial Reports:

No articles found.

Aclaris Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.